Results 41 to 50 of about 34,445,663 (284)

OAF Blocks SIAH1‐Mediated Degradation of SCPX, a Therapeutic Strategy for MASLD

Advanced Science, EarlyView.
This study shows OAF directly binds to SCPX and inhibits its interaction with the E3 ligase SIAH1, thereby protecting SCPX from ubiquitin‐dependent degradation and stabilizing its levels. This OAF‐SCPX axis represents a novel pathway in lipid homeostasis, highlighting OAF as a promising therapeutic candidate for MASLD.
Zongxi Li, Jingyue Song, Kaili Ma, Shunan Tang, Shuqian Wang, Wenya Ji, Chen Lu, Ting Zhang, Huaping Zheng, Xiaowei Zheng, Shanshan Lai, Cheng Deng   +11 more
wiley   +1 more source

A real-world propensity analysis of the impact of GLP-1 receptor agonists on cancer therapy-related cardiac dysfunction

Communications Medicine
Background Heart damage caused by cancer treatment can lead to heart failure, hospital admission, and death. Medications known as glucagon-like peptide-1 receptor agonists are widely used to treat type 2 diabetes with cardioprotective potentials. Whether
Jheng-Yan Wu, Yu-Min Lin, Mei-Chuan Lee, Chung-Han Ho, Pei Yu Jhou, Wei-Ting Chang   +5 more
doaj   +1 more source

Tirzepatide: Does the Evidence to Date Show Potential for the Treatment of Early Stage Type 2 Diabetes?

Therapeutics and Clinical Risk Management, 2022
Tanzila S Razzaki,* Alyson Weiner,* Alpana P Shukla Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism Weill Cornell Medicine, New York, NY, USA*These authors contributed equally to this ...
Razzaki TS, Weiner A, Shukla AP
doaj  

Mitochondria‐Targeted Nanotherapeutics: A Promising Strategy in Modulating Mitochondrial Function, Transfer, and Transplantation

Advanced Science, EarlyView.
This review summarizes the pathogenic role of mitochondria in diseases and highlights mitochondrial transfer and transplantation as emerging therapeutic strategies. It systematically discusses how nanomaterials are engineered to facilitate these processes, and critically examines the current challenges and future perspectives for their clinical ...
Yuanyuan Su, Zhiyan Gong, Jiao Mu, Lili Huang, Pengfei Yang, Chenli Zhang, Lingshan Zhao, Liling Yang, Jun Deng, Xiaohui Liao   +9 more
wiley   +1 more source

The glucagon-like Peptide-2 [PDF]

, 2011
Multiple peptide hormones produced within the gastrointestinal system act also in the central nervous system and aid in the regulation of energy homeostasis and metabolism. The list of these peptides is progressively increasing and includes glucagon-like
Mule, Flava, MULE', Flavia
core  

Neuroprotective effects of lixisenatide against propagation of α-synuclein pathology in Parkinson’s disease

Neural Regeneration Research
Glucagon-like peptide-1 receptor agonists, originally developed for the treatment of type 2 diabetes mellitus, have been suggested as a potential disease-modifying treatment for Parkinson’s disease.
Shangqi Sun, Liqin Huang, Gege Jiang, Guanfeng Xie, Xiaoyi Li, Xiufeng Wang, Hongxiu Guo, Cailin Wang, Siyi Zheng, Gang Li, Jing Xiong   +10 more
doaj   +1 more source

Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Ameliorates the Development of Periodontitis

Journal of Diabetes Research, 2020
Periodontitis is one of the diabetic complications due to its high morbidity and severity in patients with diabetes. The prevention of periodontitis is especially important in diabetic patients because the relationship between diabetes and periodontitis ...
Noritaka Sawada, Kei Adachi, Nobuhisa Nakamura, Megumi Miyabe, Mizuho Ito, Shuichiro Kobayashi, Shin-ichi Miyajima, Yuki Suzuki, Takeshi Kikuchi, Makoto Mizutani, Taku Toriumi, Masaki Honda, Akio Mitani, Tatsuaki Matsubara, Keiko Naruse   +14 more
doaj   +1 more source

Sonogenetic Control of Engineered Probiotics for the Treatment of MASH by Modulating the Gut‐Liver Axis

Advanced Science, EarlyView.
Researchers developed an engineered probiotic encapsulated in an inulin hydrogel, enabling ultrasound‐triggered intestinal delivery of IL‐22. In MASH model mice, this system remodeled gut microbiota, strengthened the intestinal barrier and reduced portal LPS and hepatic IL‐6.
Chunya Ji, Yan Fang, Shen Zhang, Weichen Xu, Wenyun Guo, Jing Chen, Mingrui Zhu, Congjian Wen, Siming Chen, Yuli Zhu, Huixiong Xu, Haohao Yin   +11 more
wiley   +1 more source

Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date

Diabetes, Metabolic Syndrome and Obesity, 2019
Rebecca Howell,1 Adrienne M Wright,1 Jennifer N Clements2 1Presbyterian College School of Pharmacy, Clinton, SC 29325, USA; 2Department of Pharmacy Practice, Presbyterian College School of Pharmacy, Clinton, SC 29325, USA Abstract: Metformin is the first-
Howell R, Wright AM, Clements JN
doaj  

Glucagon-like peptide-1 receptor agonists and hair loss: Current evidence and potential mechanisms

JAAD Reviews
Glucagon-like peptide-1 receptor agonists are increasingly prescribed for type 2 diabetes mellitus and obesity, with well-established benefits in glycemic control, weight reduction, and cardiometabolic outcomes.
Archie Spindler, BA, Derek Maas, BS, MBA, Grace Rachko, BA, Isabella Zappi, BA, Sahil Kapur, BS, Kermanjot Sidhu, BS, Kyle Maas, BS, Leslie Garza-García, MD, João Patrocínio, MD, Lynn Petukhova, PhD, Jerry Shapiro, MD, Kristen I. Lo Sicco, MD   +11 more
doaj   +1 more source